Fig. 5.

Inflamed phenotypes and their association with IHC subtype. (a) Inflamed phenotypes defined by hierarchical clustering (k = 2) using T cell, NK cell, and cytolytic activities in the WTS cohort. (b) Distribution of inflamed phenotype across IHC and NMF subtypes. (c) Progression-free survival by inflamed phenotype among patients treated with first-line immunotherapy. (d) Clinical benefit from front-line immunotherapy stratified by inflamed phenotype (left) and IHC subtype (right). (e) Summary of findings from this study.